U.S. markets close in 19 minutes

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.14+1.85 (+4.83%)
As of 3:41PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close38.29
Open38.31
Bid40.16 x 1100
Ask40.20 x 800
Day's Range37.65 - 41.84
52 Week Range17.00 - 55.72
Volume250,509
Avg. Volume603,958
Market Cap2.236B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Why Earnings Season Could Be Great for Generation Bio (GBIO)
      Zacks

      Why Earnings Season Could Be Great for Generation Bio (GBIO)

      Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    • Benzinga

      Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021

      Upgrades According to Ladenburg Thalmann, the prior rating for Invitae Corp (NYSE:NVTA) was changed from Neutral to Buy. For the fourth quarter, Invitae had an EPS of $0.63, compared to year-ago quarter EPS of $0.63. At the moment, the stock has a 52-week-high of $61.59 and a 52-week-low of $7.42. Invitae closed at $47.87 at the end of the last trading period. According to Maxim Group, the prior rating for Titan Pharmaceuticals Inc (NASDAQ:TTNP) was changed from Hold to Buy. The current stock performance of Titan Pharmaceuticals shows a 52-week-high of $4.30 and a 52-week-low of $0.09. Moreover, at the end of the last trading period, the closing price was at $3.55. According to Berenberg, the prior rating for Varonis Systems Inc (NASDAQ:VRNS) was changed from Hold to Buy. In the fourth quarter, Varonis Systems showed an EPS of $0.34, compared to $0.09 from the year-ago quarter. The stock has a 52-week-high of $226.00 and a 52-week-low of $48.95. At the end of the last trading period, Varonis Systems closed at $200.82. According to Credit Suisse, the prior rating for Mohawk Industries Inc (NYSE:MHK) was changed from Underperform to Neutral. Mohawk Industries earned $3.54 in the fourth quarter, compared to $2.25 in the year-ago quarter. At the moment, the stock has a 52-week-high of $178.19 and a 52-week-low of $56.62. Mohawk Industries closed at $168.84 at the end of the last trading period. For Wells Fargo & Co (NYSE:WFC), JP Morgan upgraded the previous rating of Underweight to Neutral. In the fourth quarter, Wells Fargo showed an EPS of $0.64, compared to $0.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $48.31 and a 52-week-low of $20.76. Wells Fargo closed at $36.56 at the end of the last trading period. Berenberg upgraded the previous rating for STMicroelectronics NV (NYSE:STM) from Sell to Hold. For the fourth quarter, STMicroelectronics had an EPS of $0.63, compared to year-ago quarter EPS of $0.43. At the moment, the stock has a 52-week-high of $43.02 and a 52-week-low of $14.67. STMicroelectronics closed at $41.73 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to Seaport Global, the prior rating for Andersons Inc (NASDAQ:ANDE) was changed from Buy to Neutral. In the fourth quarter, Andersons showed an EPS of $0.59, compared to $0.55 from the year-ago quarter. The stock has a 52-week-high of $29.29 and a 52-week-low of $10.00. At the end of the last trading period, Andersons closed at $27.44. For Tilray Inc (NASDAQ:TLRY), Benchmark downgraded the previous rating of Buy to Hold. Tilray earned $0.45 in the fourth quarter, compared to $0.62 in the year-ago quarter. The current stock performance of Tilray shows a 52-week-high of $67.00 and a 52-week-low of $2.43. Moreover, at the end of the last trading period, the closing price was at $31.51. For KAR Auction Services Inc (NYSE:KAR), Stephens & Co. downgraded the previous rating of Overweight to Equal-Weight. For the fourth quarter, KAR Auction Services had an EPS of $0.01, compared to year-ago quarter EPS of $0.19. The stock has a 52-week-high of $23.53 and a 52-week-low of $9.41. At the end of the last trading period, KAR Auction Services closed at $15.88. According to Baird, the prior rating for Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) was changed from Outperform to Neutral. Kratos Defense & Security earned $0.14 in the third quarter, compared to $0.09 in the year-ago quarter. The current stock performance of Kratos Defense & Security shows a 52-week-high of $34.11 and a 52-week-low of $5.00. Moreover, at the end of the last trading period, the closing price was at $33.24. For TechnipFMC PLC (NYSE:FTI), UBS downgraded the previous rating of Buy to Neutral. For the third quarter, TechnipFMC had an EPS of $0.16, compared to year-ago quarter EPS of $0.12. At the moment, the stock has a 52-week-high of $17.59 and a 52-week-low of $4.49. TechnipFMC closed at $7.79 at the end of the last trading period. For Noble Midstream Partners LP (NASDAQ:NBLX), Credit Suisse downgraded the previous rating of Outperform to Neutral. Noble Midstream Partners earned $0.44 in the fourth quarter, compared to $0.65 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.60 and a 52-week-low of $1.81. Noble Midstream Partners closed at $13.97 at the end of the last trading period. See all analyst ratings downgrades. Initiations Seaport Global initiated coverage on ConnectOne Bancorp Inc (NASDAQ:CNOB) with a Buy rating. The price target for ConnectOne Bancorp is set to $27.00. In the fourth quarter, ConnectOne Bancorp showed an EPS of $0.64, compared to $0.61 from the year-ago quarter. The stock has a 52-week-high of $24.26 and a 52-week-low of $8.86. At the end of the last trading period, ConnectOne Bancorp closed at $22.71. Wedbush initiated coverage on Dream Finders Homes Inc (NASDAQ:DFH) with a Neutral rating. The price target for Dream Finders Homes is set to $21.00. The stock has a 52-week-high of $31.98 and a 52-week-low of $17.55. At the end of the last trading period, Dream Finders Homes closed at $26.14. With a Buy rating, Jefferies initiated coverage on VistaGen Therapeutics Inc (NASDAQ:VTGN). The price target seems to have been set at $6.00 for VistaGen Therapeutics. VistaGen Therapeutics earned $0.07 in the third quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $2.94 and a 52-week-low of $0.30. VistaGen Therapeutics closed at $2.06 at the end of the last trading period. With a Hold rating, Stifel initiated coverage on McAfee Corp (NASDAQ:MCFE). The price target seems to have been set at $20.00 for McAfee. For the third quarter, McAfee had an EPS of $0.00, compared to year-ago quarter EPS of $0.02. At the moment, the stock has a 52-week-high of $22.14 and a 52-week-low of $14.80. McAfee closed at $19.28 at the end of the last trading period. With a Buy rating, Stifel initiated coverage on Cognyte Software Ltd (NASDAQ:CGNT). The price target seems to have been set at $42.00 for Cognyte Software. The stock has a 52-week-high of $33.50 and a 52-week-low of $23.75. At the end of the last trading period, Cognyte Software closed at $29.75. With a Buy rating, HC Wainwright & Co. initiated coverage on Liminal Biosciences Inc (NASDAQ:LMNL). The price target seems to have been set at $11.00 for Liminal Biosciences. In the third quarter, Liminal Biosciences earned $0.74. The stock has a 52-week-high of $31.45 and a 52-week-low of $3.51. At the end of the last trading period, Liminal Biosciences closed at $5.74. Piper Sandler initiated coverage on Infinity Pharmaceuticals Inc (NASDAQ:INFI) with an Overweight rating. The price target for Infinity Pharmaceuticals is set to $7.00. In the third quarter, Infinity Pharmaceuticals showed an EPS of $0.16, compared to $0.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.98 and a 52-week-low of $0.60. Infinity Pharmaceuticals closed at $3.81 at the end of the last trading period. With a Buy rating, Needham initiated coverage on TechTarget Inc (NASDAQ:TTGT). The price target seems to have been set at $115.00 for TechTarget. In the fourth quarter, TechTarget showed an EPS of $0.46, compared to $0.27 from the year-ago quarter. The stock has a 52-week-high of $101.12 and a 52-week-low of $16.82. At the end of the last trading period, TechTarget closed at $92.62. Needham initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ:RCKT) with a Buy rating. The price target for Rocket Pharmaceuticals is set to $75.00. In the third quarter, Rocket Pharmaceuticals showed an EPS of $0.53, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $67.48 and a 52-week-low of $9.01. At the end of the last trading period, Rocket Pharmaceuticals closed at $52.62. With a Buy rating, Needham initiated coverage on Generation Bio Co (NASDAQ:GBIO). The price target seems to have been set at $50.00 for Generation Bio. Generation Bio earned $0.46 in the third quarter, compared to $3.31 in the year-ago quarter. The stock has a 52-week-high of $55.72 and a 52-week-low of $18.80. At the end of the last trading period, Generation Bio closed at $31.79. See all analyst ratings initiations. See more from BenzingaClick here for options trades from BenzingaEarnings Outlook For Tremont MortgageAnalyzing The Price Action In West Pharmaceutical Servs Stock Today© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Generation Bio Appoints Ron Cooper to Its Board of Directors
      GlobeNewswire

      Generation Bio Appoints Ron Cooper to Its Board of Directors

      CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. Ron Cooper is a global biopharmaceutical executive who currently serves as president, chief executive officer and board member of Albireo Pharma, Inc., a position he has held since June 2015. He has successfully matured Albireo Pharma, Inc. to a clinical-stage public company on the verge of its first drug approval. Prior to joining Albireo Pharma, Inc., Cooper had a 25-year career at Bristol Myers Squibb, during which time he held multiple leadership roles in sales, marketing and general management, culminating in his role as president of Europe. “We are excited to welcome Ron to our Board of Directors during this critical stage of Generation Bio’s evolution,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “Ron is a highly seasoned and respected life sciences executive, and we look forward to his expertise, engagement and assistance as we advance our work toward the clinic. His global commercial experience and current work in rare diseases will be a great addition to our Board and organization as a whole.” “First generation gene therapy has both great promise and limitations. Generation Bio’s unique non-viral platform has the potential to significantly expand the reach of gene therapy through redosing and scale,” Cooper stated. “I look forward to joining the Board of this dynamic and growing company that could have a positive impact on patients.” About Generation Bio Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world. For more information, please visit www.generationbio.com. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, including statements about our strategic plans or objectives, our technology platforms, our research and clinical development plans, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; the Company’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; and the impact of the COVID-19 pandemic on the Company’s business and operations; as well as the other risks and uncertainties set forth in the “Risk Factors” section of our most recent quarterly report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in subsequent filings the Company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date on which they were made. Contacts: InvestorsMaren KillackeyGeneration Bio541-646-2420mkillackey@generationbio.com MediaAlicia WebbGeneration Bio847-254-4275awebb@generationbio.com Stephanie SimonTen Bridge Communications617-581-9333stephanie@tenbridgecommunications.com